Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide.

ABSTRACT: Metastatic castration resistant prostate cancer (mCRPC) is still the lethal stage for the whole spectrum of prostate cancer disease. Even though different treatment options have been introduced in the last decade with a significant survival improvement for this population, a lack of more reliable prognostic and predictive markers is still one of the main clinical challenges in management of mCRPC. The aim of this study was to investigate the correlation between Natural Killer cell activity (NKA) and both treatment effect and outcomes in patients with mCRPC treated with enzalutamide. A total of 87 patients with mCRPC treated with enzalutamide as the first line treatment were enrolled. NKA was estimated at baseline and prior to each treatment cycle. Endpoints included both treatment effect w

SUBMITTER: Zedan AH 

PROVIDER: S-EPMC10564750 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature